Last reviewed · How we verify
Desloratadine and pseudoephedrine
Desloratadine and pseudoephedrine is a Histamine-1 Receptor Antagonist [EPC] Small molecule drug developed by Dr. Reddy's Laboratories Limited. It is currently FDA-approved for Seasonal Allergic Rhinitis. Also known as: Clarinex D-24.
Desloratadine blocks histamine H1 receptors, reducing allergy symptoms; pseudoephedrine relieves nasal congestion by constricting blood vessels.
Desloratadine and pseudoephedrine, marketed by Dr. Reddy's Laboratories Limited, is a combination therapy primarily indicated for seasonal allergic rhinitis. The drug leverages the complementary mechanisms of desloratadine and pseudoephedrine to effectively manage allergy symptoms and nasal congestion, positioning it as a strong player in the allergy treatment market. The key composition patent is set to expire in 2028, which poses a significant risk of increased generic competition and potential revenue erosion.
At a glance
| Generic name | Desloratadine and pseudoephedrine |
|---|---|
| Also known as | Clarinex D-24 |
| Sponsor | Dr. Reddy's Laboratories Limited |
| Drug class | Histamine-1 Receptor Antagonist [EPC] |
| Target | H1 receptor |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Desloratadine is a histamine antagonist that selectively binds to H1 receptors, preventing histamine from causing allergy symptoms like itching and sneezing. Pseudoephedrine acts as a decongestant by narrowing blood vessels in the nasal passages, reducing swelling and congestion.
Approved indications
- Seasonal Allergic Rhinitis
Common side effects
- Mouth Dry
- Nausea
- Fatigue
- Anorexia
- Headache
- Somnolence
- Dizziness
- Insomnia
- Pharyngitis
Key clinical trials
- Bioequivalence Study of Desloratadine and Pseudoephedrine Extended-release Tablets Under Fed Conditions (PHASE1)
- Bioequivalence Study of Desloratadine and Pseudoephedrine Sulfate Extended-release Tablets Under Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Desloratadine and pseudoephedrine CI brief — competitive landscape report
- Desloratadine and pseudoephedrine updates RSS · CI watch RSS
- Dr. Reddy's Laboratories Limited portfolio CI
Frequently asked questions about Desloratadine and pseudoephedrine
What is Desloratadine and pseudoephedrine?
How does Desloratadine and pseudoephedrine work?
What is Desloratadine and pseudoephedrine used for?
Who makes Desloratadine and pseudoephedrine?
Is Desloratadine and pseudoephedrine also known as anything else?
What drug class is Desloratadine and pseudoephedrine in?
What development phase is Desloratadine and pseudoephedrine in?
What are the side effects of Desloratadine and pseudoephedrine?
What does Desloratadine and pseudoephedrine target?
Related
- Drug class: All Histamine-1 Receptor Antagonist [EPC] drugs
- Target: All drugs targeting H1 receptor
- Manufacturer: Dr. Reddy's Laboratories Limited — full pipeline
- Indication: Drugs for Seasonal Allergic Rhinitis
- Also known as: Clarinex D-24
- Compare: Desloratadine and pseudoephedrine vs similar drugs
- Pricing: Desloratadine and pseudoephedrine cost, discount & access